Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
3.030
-0.020 (-0.66%)
Nov 16, 2026, 4:00 PM EST - Market closed

Protalix BioTherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
84.6952.7453.465.4947.6438.35
Revenue Growth
36.95%-1.23%-18.47%37.48%24.22%-39.03%
Gross Profit
41.426.8616.726.2-0.7922
Operating Income
25.21-5.53.9210.46-13.01-20.46
Net Income
20.55-6.62.938.31-14.93-27.58
Earnings Per Share
0.25-0.080.040.09-0.31-0.62
EPS Growth
256.60%--57.71%---

Revenue by Segment

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Pfizer (Ireland)
12.8618.2312.6212.5212.410.16
Fiocruz (Brazil)
10.2711.0611.0310.49.456.4
Chiesi (Italy)
34.6422.5129.3317.53.440.19
Revenue from License and R&D Services
26.920.940.4225.0822.3521.6
Revenue (Total)
84.6952.7453.465.4947.6438.35

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
48.5430.2734.8344.5622.1838.99
Total Debt
9.158.325.5326.2833.4733.47
Net Cash (Debt)
39.3921.9529.318.28-11.295.52
Net Cash Growth
85.88%-25.09%60.31%---
Net Cash Per Share
0.480.280.360.22-0.230.12

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
17.56-11.998.67-1.32-25-10.29
Capital Expenditures
-2.49-1.64-1.28-1.15-0.63-1.46
Free Cash Flow
15.07-13.637.39-2.47-25.63-11.74
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
48.91%13.01%31.27%40.00%-1.65%57.37%
Operating Margin
29.76%-10.43%7.33%15.97%-27.32%-53.36%
Pretax Margin
30.52%-10.63%7.78%13.08%-30.22%-71.92%
Profit Margin
24.27%-12.52%5.49%12.69%-31.33%-71.92%
FCF Margin
17.79%-25.84%13.84%-3.77%-53.80%-30.62%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
12.30-47.2115.62--
Forward PE
25.2510.293.9413.1760.89111.67
P/FCF Ratio
16.96-18.73---
PS Ratio
3.022.752.591.981.460.99